News Brexit could marginalise UK life sciences - expert Cancer doctor concerned over impact on life sciences R&D.
News Vasopharm drug could limit damage caused by brain injuries German biotech moves into phase 3 after a long wait
News Novartis move damages CAR-T confidence Swiss pharma axes gene therapy unit, causing investor angst.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
